The US Food and Drug Administration (FDA) has approved Eli Lilly’s Zepbound – a powerful new medicine for weight loss for adults with obesity or who are overweight and have at least one related health condition.
The drug, which was already available to treat Type 2 diabetes under the brand name Mounjaro, is one of a class of medicines known as GLP-1 agonists that have revolutionized the treatment of obesity.
GLP-1 agonists activate a receptor for a gut hormone of the same name, and are thought to work by reducing appetite and slowing gastric emptying.
While early versions of GLP-1 agonists had only modest effects, newer drugs like Wegovy, Mounjaro and Novo’s Ozempic offer better blood sugar control and more substantial weight loss. Their success has helped make GLP-1 therapies a dominant treatment type for metabolic disease.
To find out more, CLICK HERE.
